US Patent

US12383503 — Adagrasib solid pharmaceutical compositions

Formulation · Assigned to Mirati Therapeutics Inc · Expires 2043-08-21 · 17y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects solid pharmaceutical compositions of adagrasib for oral dosage to treat cancer, as well as methods for manufacturing and treating cancer.

USPTO Abstract

Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US12383503
Jurisdiction
US
Classification
Formulation
Expires
2043-08-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.